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ABSTRACT
Background Medication information is often poorly
delineated for paediatric patients, resulting in high
oﬀ-label and non-licensed use of drugs in this
population. Access to accurate medicines infor-
mation in this population becomes a necessity in
order to avoid medication errors. Clinical decision
support tools (CDSTs), which are increasingly avail-
able on mobile devices (e.g. smartphones), can pro-
vide healthcare providers with convenient access to
paediatric medicines information at point of care.
However, to date no systematic evaluation of the
content in these CDSTs has been conducted.
Objectives To evaluate paediatricmedicines infor-
mation in CDSTs for smartphones and other mo-
bile devices.
Method Evaluation of CDSTs according to scope
and completeness was accomplished via weighted
categories of 108 questions distributed evenly across
three age groups: infants, children and adolescents.
Results Three paediatric-speciﬁc databases and six
general databases were evaluated. The best per-
former provided 75.9% of the answers for scope
and scored 69.7% for completeness. Databases
generally performed less eﬀectively in providing
answers sourced from clinical guidelines compared
with more conservative sources such as package
inserts.
Conclusions Overall, general medicines infor-
mation CDSTs performed better than paediatric-
speciﬁc CDSTs in both scope and completeness.
Results from this study may help guide CDST
selection on mobile devices by healthcare profes-
sionalswhose patient populations include paediatrics.
Keywords: clinical decision support tools, drug
information databases, handheld computers,
paediatrics
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Introduction
Medication safety and dosing information is often
poorly delineated for paediatric patients as 75% of
medications demonstrate insuﬃcient labelling for
these two purposes.1 This has resulted in the common
practice of oﬀ-label or unlicensed use of medications
in paediatric patients.2,3 Exacerbating matters for
paediatric patients is the threat of medication errors.
Children are more susceptible than adults to medica-
tion errors due to amore narrow therapeutic window,
poorly deﬁned medicines information and variability
in weight and body surface area, thus complicating
pharmacokinetic and pharmacodynamic consider-
ations.4 However, a landmark study by Leape et al
found the most common system failure associated
with preventable medical errors was proper dissemi-
nation of medicines information.5 The use of clinical
decision support tools (CDSTs) is one strategy that
has demonstrated an ability to help prevent medi-
cation errors in paediatrics.6
One type of CDST, which is often housed on
smartphones (e.g. iPhone, Blackberry) or other mo-
bile devices (e.g. iPad, TabletPC), is the medicines
information database. This tool can help to directly
address the issue of medicines information dissemi-
nation and its value is enhanced by being available at
the point of care. A growing number of healthcare
professionals (HCPs) have adopted the use of these
tools. In particular, paediatricians (80%)7 and paediatric
residents (89.5%)8 report commonly using drug ref-
erences. However, to date no study has evaluated the
ability of CDSTs to provide complete and correct
paediatric medicines information. Additionally, no
guidance is available to assist HCPs in selecting a
particular CDST for paediatric medicines information.
The aim of this study was to evaluate paediatric-
related medicines information in CDSTs available
on smartphones and mobile devices with regard to
scope and completeness.
Methods
Question and category development
Seven categories of medicines information questions
were developed, including dosing, indications/contra-
indications, adverse reactions, pharmacokinetics, mon-
itoring, drug interactions and formulations. These
categories were selected andweighted based on impact
on direct patient care. Category weighting was designed
to mirror the distribution of the types of medication
use questions encountered in clinical practice. Within
each category, questions were evenly subdivided into
three speciﬁc age groups: infants, children and ado-
lescents. A total of 108 question and answer pairs were
created to populate the categories, with an even dis-
tribution of 36 questions across each age group.
Answers were generated from conservative, estab-
lished sources (i.e. package inserts) for 75% of the
questions. Owing to the high level of oﬀ-label and
unlicensed use in paediatric patients, 25% of the
answers were derived from paediatric clinical practice
guidelines. All aspects of the study methodology (e.g.
category and question design, category weighting, ques-
tion and answer accuracy, relevance to practice) were
reviewed by an external panel of paediatricians and
pharmacists with expertise in the ﬁeld of paediatrics.
Changes weremade based on the recommendations of
the panel. A sample of speciﬁc medicines information
questions is provided in Box 1.
Database selection
Both general and paediatric-speciﬁc CDSTs were
included for evaluation. Inclusion criteria for CDSTs
required a satisfactory breadth of information and
an electronic downloadable format. ‘Satisfactory’ was
deﬁned as the capacity of a particular database to
answer questions in at least ﬁve of the seven categories.
This criterion insured the medicines information the
CDST contained was broad in nature and not too
narrow in scope. CDSTs were excluded if they func-
tioned strictly as a specialty database (e.g. a reference
comprised exclusively of stability–compatibility data
or one limited to identiﬁcation of drug interactions).
Three paediatric-speciﬁc and six general medicines
information CDSTs satisﬁed all of the inclusion criteria.
Paediatric-speciﬁc CDSTs included: British National
Formulary for Children (BNFC), Harriet Lane Hand-
book (HLH) and Paediatric Lexi-Drugs (PLD). Gen-
eral CDSTs included: A to Z Drug Facts (A2Z),
Box 1 Sample of medicines information
questions
. Can the sudden appearance of extrapyramidal
symptoms in an 11-month-old infant be attrib-
uted to administration of metoclopramide by
injection?
. What vital signs must be monitored during
immune globulin infusion in a 4-year-old with
Kawasaki’s disease?
. Why should a 17-year-old patient avoid taking
drospirenone and ethinyl estradiol and St John’s
Wort (hypericum perforatum) concurrently?
. At what concentration is caﬀeine citrate for
injection available?
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American Hospital Formulary Service Drug Infor-
mation (AHFS), Clinical Pharmacology OnHand
(CP), Epocrates Rx Pro (ERP), Lexi-Drugs (LD) and
Thomson Clinical Xpert (TCX). Information on the
databases included in the study is shown in Table 1.
Database assessment
Databases were evaluated on two qualities: scope and
completeness. Scope was measured by the presence or
absence of an answer and was assessed for all 108
questions in all databases. A score of one was assigned
if an answer was found and, conversely, a score of zero
was assigned if an answer was absent. The scope for
each CDST was calculated as a percentage based on
the number of answers it yielded. Completeness was a
measure of depth deﬁned as a correct, accurate answer.
Completeness was assessed on a scale of one to three,
with one being the least complete and three being the
most complete. If a database scored a zero for scope,
then that database also scored a zero for completeness.
The completeness scores were calculated and reported
as a percentage. Two sets of averages were calculated
for the completeness score, one for questions from
conservative, established sources and one from clini-
cal practice guidelines. Each question was assessed
independently by two authors and if discrepancies in
scoring occurred, discussion ensued until a consensus
was reached.
Each discrete CDST was individually evaluated for
scope and completeness and the results were also calcu-
lated for each question category and age group. Add-
itionally, an overall score combining all results for each
category and age group was generated for each CDST.
Statistical analysis
Descriptive statistics were used to summarise the
evaluative components. A repeated measures analysis
of variance (ANOVA) was used to determine whether
signiﬁcant diﬀerences existed for both scope and
completeness scores between general and paediatric-
speciﬁc databases. Statistical analysis of results was
conducted using SPSS version 16.0. Signiﬁcance was
set at the 0.05 level.
Table 1 Database information
Databases Abbreviation Publisher Website for additional
information
General
A to Z Drug Facts A2Z Wolters Kluwer
Health
www.factsandcomparisons.com
American Hospital Formulary
Services Drug Information
AHFS American Society of
Health-System
Pharmacists
www.ashp.org
CP OnHand CP Elsevier, Inc www.clinicalpharmacology.com
Epocrates RX Pro ERP Epocrates www.epocrates.com
Lexi-Drug LD Lexi-Comp, Inc www.lexi.com
Thomson Clinical Xpert TCX Thomson Reuters www.micromedex.com
Paediatric-speciﬁc
British National Formulary for
Children
BNFC RPS Publishing www.bnf.org
Harriet Lane Handbook HLH Johns Hopkins
Hospital
www.skyscape.com
Pediatric Lexi-Drug PLD Lexi-Comp, Inc www.lexi.com
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Results
Scope of databases
The top performing database with regard to scope was
PLD, with the ability to provide answers to 75.9% of
the questions. The lowest scoring database for scope
was BNFC (28.7%), which means both the best and
worst performing CDSTs were paediatric-speciﬁc
databases. Full details of database scope scores for all
CDSTs are delineated in Table 2. After all scope scores
were calculated, analysis revealed signiﬁcant diﬀer-
ences between CDSTs (P0.01).
Completeness of databases
In terms of completeness of databases, PLD averaged
69.7% completeness and BNFC scored lowest of the
Table 2 Scope of general and paediatric-speciﬁc drug information databases
General
Category n A2Z AHFS CP ERP LD TCX BNFC HLH PLD
Dosing 21 14 17 13 15 15 13 2 8 13
Infant 7 5 7 6 7 6 5 1 2 6
Child 7 4 5 2 2 3 2 0 3 3
Adolescent 7 5 5 5 6 6 6 1 3 4
Indications/
contraindications
18 10 11 10 10 10 12 7 8 13
Infant 6 3 3 3 3 2 3 3 3 5
Child 6 5 5 4 5 6 6 2 3 6
Adolescent 6 2 3 3 2 2 3 2 2 2
Adverse reactions 18 14 16 11 16 17 16 9 10 17
Infant 6 4 5 3 6 5 5 3 5 6
Child 6 5 5 4 4 6 5 3 2 6
Adolescent 6 5 6 4 6 6 6 3 3 5
Pharmacokinetics 15 4 5 0 0 4 3 0 0 6
Infant 5 1 3 0 0 2 2 0 0 3
Child 5 2 2 0 0 1 0 0 0 3
Adolescent 5 1 0 0 0 1 1 0 0 0
Monitoring 12 9 7 1 8 5 9 2 2 11
Infant 4 2 0 0 2 2 2 0 1 3
Child 4 3 3 0 3 1 3 0 0 4
Adolescent 4 4 4 1 3 2 4 2 1 4
Drug interactions 12 11 8 12 11 10 8 8 6 10
Infant 4 3 2 4 3 3 2 2 2 4
Child 4 4 3 4 4 4 3 3 2 4
Adolescent 4 4 3 4 4 3 3 3 2 2
Formulations 12 7 8 7 4 10 8 3 4 12
Infant 4 3 3 3 1 3 2 3 2 4
Child 4 1 2 1 1 3 3 0 1 4
Adolescent 4 3 3 3 2 4 3 0 1 4
TOTAL 108 69 72 54 64 71 69 31 38 82
% 100 63.9 66.7 50.0 59.3 65.7 63.9 28.7 35.2 75.9
n=number of questions per category; A2Z=A to Z Drug Facts; AHFS= American Hospital Formulary Service Drug Information;
CP=Clinical Pharmacology OnHand; ERP=Epocrates RX Pro; LD=Lexi-Drug; TCX=Thomson Clinical Xpert; BNFC=British
National Formulary for Children; HLH=The Harriet Lane Handbook; PLD=Pediatric Lexi-Drug
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databases at only 23.4%.Table 3 provides full details of
completeness data for each database. Completeness
scores were similarly found to be signiﬁcantly diﬀerent
(P0.01).
Comparison of paediatric-speciﬁc and
general databases
Performances between paediatric-speciﬁc and general
databases were not signiﬁcantly diﬀerent for either
scope or completeness. Although a paediatric-speciﬁc
CDST performed best in terms of scope, the overall
scores for scope in paediatric-speciﬁc databases were
not signiﬁcantly better than those of the general data-
bases. The reverse actually held true as general medi-
cines information references scored an average of
61.6% in scopewhile paediatric-speciﬁc databases scored
only an average of 46.6%. In terms of completeness,
general CDSTs again outperformed paediatric-speciﬁc
CDSTs with an average score of 53.9% versus 42.0%.
Comparison of package insert and
clinical practice guideline-based
questions
Most paediatric CDSTs performed better for scope in
questions derived from authoritative but conservative
sources (e.g. package inserts) versus those answers
were sourced from clinical guidelines. For questions
frompackage inserts, BNFC scored the lowest in scope
at 33.0% andAHFS the highest at 71.7%. In the clinical
practice guideline-based questions, BNFC scored the
lowest in scope at 13.3% and PLD the highest at
63.2%.
In terms of completeness, all CDSTs performed
better in questions derived from package inserts,
with PLD performing the best and BNFC the worst
with 78.3% and 12.3% average completeness respect-
ively. For questions derived from clinical practice
guidelines, PLD was the top performer at 59.7% and
BNFC the lowest at 12.3% average score for complete-
ness.
Discussion
Principal ﬁndings
A misconception may exist that paediatric-speciﬁc
medicines information databases are better for paedi-
atrics than general medicines information databases.
While the best overall performer was paediatric speciﬁc,
as a group specialty databases performed poorly and
typically were only able to answer one-half as many
questions as their general counterparts. This is an im-
portant distinction as HCPs who generally acknowl-
edge ‘gold standard’ references such as HLH as their
primary medicines information source may be sur-
prised at how ineﬀective it was in providing basic
Table 3 Completeness (%) of general and paediatric-speciﬁc drug information databases
General
Category n A2Z AHFS CP ERP LD TCX BNFC HLH PLD
Dosing 28 60.7 75.0 64.3 60.7 66.7 64.3 7.1 40.5 63.1
Indications/
contraindications
24 43.1 55.6 52.8 47.2 56.9 62.5 34.7 41.7 69.4
Adverse reactions 24 66.7 84.7 51.4 76.4 80.6 66.7 38.9 47.2 86.1
Pharmacokinetics 20 23.3 33.3 0 0 18.3 23.3 0 0 38.3
Monitoring 16 52.1 54.2 6.3 56.3 25.0 60.4 14.6 16.7 77.1
Drug interactions 16 56.3 58.3 87.5 83.3 75.0 52.1 52.1 39.6 68.8
Formulations 16 50.0 56.3 47.9 29.2 77.1 56.3 20.8 35.4 89.6
TOTAL % 100 50.9 61.3 45.6 51.2 58.1 56.0 23.4 32.9 69.7
n=number of questions per category; A2Z=A to Z Drug Facts; AHFS= American Hospital Formulary Service Drug Information;
CP=Clinical Pharmacology OnHand; ERP=Epocrates RX Pro; LD=Lexi-Drug; TCX=Thomson Clinical Xpert; BNFC=British
National Formulary for Children; HLH=The Harriet Lane Handbook; PLD=Pediatric Lexi-Drug
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information about medications (e.g. adverse reac-
tions, drug interactions and dosing).
Implications of the ﬁndings
The results from this study can be used to guide HCPs
to select the CDST that best suits their individual
practice needs. For example, since scope and com-
pleteness scores are reported by both category and
patient subpopulation, the HCP who is primarily
interested in dosing information could choose the data-
base that performed best in that capacity. Similarly, if
drug interaction information is the primary concern,
the data could be used to eliminate possible CDST
choices from contention. Additionally, institutions con-
sidering adopting smartphone or mobile device CDSTs
to reduce adverse drug events (ADEs) can utilise the
results of this study to drive decision making and help
provide budgetary justiﬁcation. The results of our
study may be further underscored by the ﬁndings of
an interventional study in which the mobile device-
based use of PLD (the highest overall performer in our
study) was implemented and resulted in the signiﬁ-
cant reduction of 7.1 potential ADEs per 100 orders
(P=0.001).9
One notable categorical performance (irrespective
of database) was pharmacokinetic information. Of the
full CDSTs that were studied, the average number of
questions answered correctly was 1.4 out of 16, with
no single database able to provide answers for one-half
of the questions.Questions regarding trough and peak
concentrations, clearance, volume of distribution and
bioavailability went largely unanswered by databases,
despite the dire need for information in these areas in
paediatrics due to weight and body surface variability.
This is an area that practitioners should recognise as a
limitation in these CDSTs.
Comparison with the literature
The use of smartphones by physicians has rapidly
increased over the past few years, far outstripping
the rate of adoption by the general population.10 Just
ten years ago, physician use of mobile phones hovered
around 30%, whereas 72% of physicians currently use
smartphones and it is believed that number will grow
to 81% by 2012.10 Mobile devices have been used
speciﬁcally in paediatrics for a variety of applications
including depression screening,11 measuring clinical
and educational workload12 and improving resident
documentation discrepancies.13 However, the most
commonly used application is the medicines infor-
mation database, and studies have demonstrated that
CDSTs can help decrease the rate of medication errors
in the paediatric population.6,9,14 One study speciﬁcally
found that the introduction of a mobile device-based
medicines information reference signiﬁcantly reduced
potential ADEs in a children’s hospital (P=0.001).9
Databases used as CDSTs on smartphones andmobile
devices have previously been assessed for general
medicines information,15–18 and content from these
medicines information databases has also been assessed
in order to rate the potential to reduce medication
errors.19 Although there are several studies highlighting
the accuracy of general and selected specialty medi-
cines information references, there are no published
studies systematically evaluating smartphone databases
for paediatric medicines information.
Because of the limited number of medications with
approved indications in paediatric patients, the avail-
ability of appropriate medicines information to the
HCP is vital. Eﬃcacy and safety data from manufac-
turers is often scarce and provides limited utility for
determining the appropriate dosage for paediatric
patients. Subsequently, HCPs may rely heavily on
CDSTs for guidance. Incomplete or inaccurate infor-
mation may result in treatment failure or adverse
consequences. For example, one question included
in the study evaluated the scope and completeness for
the dosing of acyclovir for the treatment of herpes
simplex virus (HSV) encephalitis. The acyclovir dose
for HSV central nervous system infections from birth
to threemonths is listed in the package insert as 10mg/
kg every eight hours for ten days.20 The insert further
states that doses of 15–20 mg/kg/dose have also been
used, but safety has not been established.20 However,
the American Academy of Pediatrics (AAP) Red Book
recommends a dosage of 20 mg/kg/day every eight
hours for 21 days.21 Of the databases reviewed in this
study, four of nine (44%) did not meet either scope or
completeness for this particular question, including
two of the paediatric-speciﬁc CDSTs (i.e. HLH and
PLD). Subtherapeutic dosing of acyclovir in HSV
encephalitis has the potential to result in long-term
sequelae, such as brain damage. Another area for poten-
tial therapeutic failure is in the treatment of acute
otitis media. The most recent AAP clinical guidelines
recommend an oral dose of amoxicillin of 80–90 mg/
kg/day in two divided doses for ten days.22 In our
study, we found that only one of the databases earned
full scores in both scope and completeness for this
particular question, four years after the release of the
guidelines.
Actual adverse events secondary to inaccurate in-
formation in CDSTs are unknown. To date, only one
paediatric case report has been published regarding
errors in CDSTs. In the report, a one-month-old infant
presented to the emergency department with symp-
toms of phenytoin toxicity with a serum phenytoin
concentration of 91.8 mcg/mL. Upon investigation, it
was realised that the infant had been prescribed
phenytoin 2.5mL of the 30mg/5mL suspension based
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on the information available in a speciﬁc CDST. At the
time, the 30mg/5mL suspensionwas not available and
the pharmacist dispensed an incorrect dose.23 Inap-
propriate dosing resulting in ADEs may not be
recognised as frequently in the outpatient setting as
in the inpatient setting due to fewer monitoring
programmes being available in the outpatient setting.
One study, however, did ﬁnd that the potential inci-
dence of outpatientmedication dosing errors can be as
high as 15%,24 hence the occurrence of similar adverse
events in the outpatient environment may not be
captured.
Limitations of the method
Not all available CDSTs were evaluated in this study,
nor were all possible clinical questions evaluated. HCPs
may use diﬀerent resources for speciﬁc types of infor-
mation than those examined in this study (e.g. using a
drug interaction database to identify speciﬁc drug
interactions). However, the most commonly used
comprehensive CDSTs were identiﬁed and included
in the study. Additionally, while only a subset of all
possible evaluation questions was used, the selected
categories, age groups and questions were all designed
to be a representative sample.
All answers in the evaluation were veriﬁed by either
the package insert or clinical practice guidelines to
minimise diﬀerences in opinions based on clinical
practice. However, the overall frequency of guideline
non-adherence by HCPs is unknown and practice
guidelines speciﬁc to the USA were primarily used.
One study evaluated trends in the management of
otitis media since the release of the last AAP guide-
lines.25 The study showed that of the physicians
responding to the survey 57.2% utilised high-dose
amoxicillin in patients with non-severe symptoms,
but 33.1% continued to prescribe amoxicillin at the
traditional, conservative dose. The authors speculated
that possible reasons for non-adherence to the guide-
lines included lack of knowledge about the guidelines,
lack of agreement with the guidelines or pharmaceutical
industry inﬂuence on prescribing. As stated previously,
only one of the CDSTs in this evaluation was able to
fully answer the otitis media dosing question with
regard to scope and completeness, whichmay provide
an additional reason for lack of adherence to the
guidelines.
Call for further research
A potential limitation of our study is that only 25% of
the questions included were based on clinical practice
guidelines. However, because this is the ﬁrst evalu-
ation of paediatric-speciﬁc CDSTs, it was decided to
focus primarily on questions with answers from
sources that were not subject to debate. Future evalu-
ations of paediatric medicines information in CDSTs
may include a higher percentage of clinical practice
guideline questions in order to more closely resemble
clinical practice.
Conclusion
Noprevious systematic and objective evaluations have
been conducted to assess the quality of medicines
information in CDSTs for paediatrics. Surprisingly,
general medicines information CDSTs collectively out-
performed paediatric-speciﬁc databases in the pro-
vision of medicines information. However, PLD was
the best overall performer in answering medicines
information questions. Overall, general and paediatric-
specialty databases have substantial limitations in
providing paediatric medicines information. Publishers
should re-examine the inclusion of information drawn
from clinical guidelines given the frequency of oﬀ-
label and unlicensed use in the paediatric population.
The results from this study may help guide CDST
selection by paediatricians and other HCPs whose
patient populations include paediatrics.
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